| Press releases

Formycon Publishes Figures for the First Quarter of 2017

The commercial performance of Formycon has again advanced as planned in the first quarter of 2017 and the development of its four biosimilar projects has progressed as expected.


German Equity Forum

November 27-29, 2017; Frankfurt/Germany

Financial reports

Annual Report 2016

Published on:
May 3, 2017

  • Teaser_mitglied-bio-deutschland-en
  • Forschungssiegel_Teaser_Webseite-en
  • Teaser_mitglied-biosimilar-medicines-en
  • teaser-powerlist
  • teaser-wachstumschampion-en
  • pipeline-en-teaser
  • slider04
  • slider06

Formycon is a leading independent pure play developer of biosimilars and has become a recognized innovator in this field. The company has extensive experience in the development of complex biological molecules. Formycon’s specialist expertise allows the company to develop high-quality biosimilars that meet the strict regulatory requirements of highly regulated markets such as Europe and the United States. Formycon currently has four biosimilars under development, with further product candidates already identified. Two biosimilar candidates have already been licensed out.